Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis
Authors:
- R. LopesRLR. Lopes
- C.V. EleutérioCEC.V. Eleutério
- L.M.D. GonçalvesL.M.D. Gonçalves
- M.E.M. CruzMCM.E.M. Cruz
- A.J. AlmeidaAAA.J. Almeida
- 1 March 2012
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 45 (4) , 442-450
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Effect of lipid types on physicochemical characteristics, stability and antioxidant activity of gamma-oryzanol-loaded lipid nanoparticlesJournal of Microencapsulation, 2009
- Structural and biological characterization of the tubulin interaction with dinitroanilinesCytology and Genetics, 2009
- Spread of Vector-borne Diseases and Neglect of Leishmaniasis, EuropeEmerging Infectious Diseases, 2008
- Influence of preparation conditions and heat treatment on the properties of supercooled smectic cholesteryl myristate nanoparticlesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2007
- Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: CharacterizationEuropean Journal of Pharmaceutics and Biopharmaceutics, 2007
- Pre-systemic metabolism prevents in vivo antikinetoplastid activity of N1,N4-substituted 3,5-dinitro sulfanilamide, GB-II-150Life Sciences, 2006
- Leishmania–Host-cell Interaction: Complexities and Alternative ViewsParasitology Today, 2000
- Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersionsInternational Journal of Pharmaceutics, 1998
- Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanismEuropean Journal of Pharmaceutics and Biopharmaceutics, 1998
- Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticlesInternational Journal of Pharmaceutics, 1997